These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

696 related items for PubMed ID: 18704282

  • 21. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
    Pollock RF, Curtis BH, Valentine WJ.
    J Med Econ; 2012; 15(4):766-75. PubMed ID: 22413830
    [Abstract] [Full Text] [Related]

  • 22. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S67-73. PubMed ID: 15324518
    [Abstract] [Full Text] [Related]

  • 23. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

  • 24. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group.
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [Abstract] [Full Text] [Related]

  • 25. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study.
    Almbrand B, Johannesson M, Sjöstrand B, Malmberg K, Rydén L.
    Eur Heart J; 2000 May; 21(9):733-9. PubMed ID: 10739728
    [Abstract] [Full Text] [Related]

  • 27. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA.
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
    Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.
    Diabetes Obes Metab; 2009 Nov; 11(11):1068-79. PubMed ID: 19732121
    [Abstract] [Full Text] [Related]

  • 29. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 30. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ.
    J Med Econ; 2012 Jan; 15(5):977-86. PubMed ID: 22563742
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
    Palmer JL, Knudsen MS, Aagren M, Thomsen TL.
    J Med Econ; 2010 Jan; 13(2):212-20. PubMed ID: 20350145
    [Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU.
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [Abstract] [Full Text] [Related]

  • 33. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
    Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C, PROactive Study Group.
    Value Health; 2009 Nov; 12(1):1-9. PubMed ID: 18657104
    [Abstract] [Full Text] [Related]

  • 34. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
    Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.
    Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
    [Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes.
    Schouten LM, Niessen LW, van de Pas JW, Grol RP, Hulscher ME.
    Med Care; 2010 Oct; 48(10):884-91. PubMed ID: 20808258
    [Abstract] [Full Text] [Related]

  • 36. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL.
    Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
    [Abstract] [Full Text] [Related]

  • 37. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ, Tucker DM.
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [Abstract] [Full Text] [Related]

  • 38. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, Saaddine JB.
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
    Yang L, Christensen T, Sun F, Chang J.
    Value Health; 2012 May; 15(1 Suppl):S56-9. PubMed ID: 22265068
    [Abstract] [Full Text] [Related]

  • 40. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012 May; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.